Large Outflow of Money Witnessed in Astrazeneca PLC

Astrazeneca PLC (AZN) : The total money flow in Astrazeneca PLC (AZN) was negative ($0.69 million), showing the domination of sellers in the Monday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $1.95 million. Transactions on upticks were comparatively lower at $1.26 million. The uptick to downtick ratio was 0.65. The total block trades done on upticks were valued at $0.35 million. The total block trades on downticks were valued at $1.3 million. The uptick to the downtick ratio of block trades was 0.27. The money flow during block trades was negative ($0.95 million) when the stock traded with a gain of $30 cent. Astrazeneca PLC (AZN) was $30.54, an increase of 0.99% over the previous days close.


AstraZeneca PLC is up 1.16% in the last 3-month period. Year-to-Date the stock performance stands at -7.1%. Shares of AstraZeneca PLC rose by 1.94% in the last five trading days and 10.57% for the last 4 weeks.

Astrazeneca PLC (NYSE:AZN): stock turned positive on Monday. Though the stock opened at $30.48, the bulls momentum made the stock top out at $30.63 level for the day. The stock recorded a low of $30.445 and closed the trading day at $30.55, in the green by 1.03%. The total traded volume for the day was 5,850,035. The stock had closed at $30.24 in the previous days trading.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.